<?xml version="1.0" encoding="UTF-8"?>
<p>Antioxidant peptides have been isolated from a range of marine organisms (
 <xref rid="marinedrugs-18-00627-t004" ref-type="table">Table 4</xref>), from the smallest marine rotifer (
 <italic>Brachionus rotundiformis</italic>) [
 <xref rid="B241-marinedrugs-18-00627" ref-type="bibr">241</xref>], oysters (
 <italic>Crassostrea gigas</italic>) [
 <xref rid="B234-marinedrugs-18-00627" ref-type="bibr">234</xref>], different marine vertebrates and invertebrates [
 <xref rid="B236-marinedrugs-18-00627" ref-type="bibr">236</xref>], and marine by-products [
 <xref rid="B235-marinedrugs-18-00627" ref-type="bibr">235</xref>,
 <xref rid="B242-marinedrugs-18-00627" ref-type="bibr">242</xref>]. The antioxidant properties of peptides are commonly determined based on different in vitro assays, e.g., scavenging of free radicals (2,2-diphenyl-1-picrylhydrazyl, hydroxyl, superoxide), reducing ferric iron to ferrous, binding of metals (metal chelation), and inhibiting lipid oxidation. However evidence of the in vivo antioxidant capacity as well as cellular studies of peptides are a necessary step before human clinical trials [
 <xref rid="B236-marinedrugs-18-00627" ref-type="bibr">236</xref>]. The biological potential of marine antioxidant peptides with human clinical trials is limited [
 <xref rid="B243-marinedrugs-18-00627" ref-type="bibr">243</xref>].
</p>
